ANIP vs RARE: stock comparison and AI forecast
Ani Pharmaceuticals Inc (ANIP) and Ultragenyx Pharmaceutical Inc. (RARE) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ANIP Ani Pharmaceuticals Inc
- Market Cap
- $1.62B
- P/E Ratio
- 13.4x
- Size
- small-cap
- AI Forecast
RARE Ultragenyx Pharmaceutical Inc.
- Market Cap
- $1.61B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- ANIP and RARE have similar market capitalizations ($1.62B and $1.61B).
- ANIP turns 734.8% of its revenue into net income, against -100.8% for RARE.
- ANIP yields 0.02% in dividends; RARE pays none.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ANIP | RARE |
|---|---|---|
| Market Cap | $1.62B | $1.61B |
| P/E Ratio | 13.36x | – |
| P/B Ratio | 2.72x | – |
| Dividend Yield | 0.02% | – |
| EPS | $5.29 | $-5.83 |
| Book Value/Share | $26.01 | – |
| Revenue/Share | $0.64 | $5.90 |
| FCF/Share | $7.53 | $-4.96 |
Profitability & Margins
| Metric | ANIP | RARE |
|---|---|---|
| ROE | 18.1% | – |
| ROA | 7.2% | -46.4% |
| ROIC | 12.4% | -57.9% |
| Gross Margin | -2528.2% | – |
| Operating Margin | 1020.0% | -90.9% |
| Net Margin | 734.8% | -100.8% |
| EBT Margin | 967.4% | -100.2% |
| Tax Rate | 24.0% | -0.6% |
Financial Health
| Metric | ANIP | RARE |
|---|---|---|
| Current Ratio | 2.91x | 1.73x |
| Quick Ratio | 2.41x | 1.56x |
| D/E Ratio | 1.50x | – |
| Financial Leverage | 2.50x | – |
| Interest Coverage | 5.4x | -32.5x |
| Working Capital | $542M | $255M |
Cash Flow
| Metric | ANIP | RARE |
|---|---|---|
| Operating Cash Flow | $189M | -$485M |
| Free Cash Flow | $173M | -$489M |
| Capital Spending | -$16M | -$4M |
| OCF Growth YoY | 36.2% | – |
| FCF Growth YoY | 37.9% | – |
| FCF/Sales | 1173.6% | -84.2% |
| CapEx/Sales | 111.8% | 0.7% |
Operational Efficiency
| Metric | ANIP | RARE |
|---|---|---|
| Asset Turnover | 0.01x | 0.46x |
| Receivables Turnover | 0.1x | 2.9x |
| Inventory Turnover | 2.7x | – |
| Fixed Assets Turnover | 0.2x | 2.5x |
| Days Sales Outstanding | 6797 days | 126 days |
| Days Inventory | 135 days | – |
| Payables Period | 70 days | – |
| Cash Conversion Cycle | 6862 days | – |
Income Statement
| Metric | ANIP | RARE |
|---|---|---|
| Total Revenue | $15M | $581M |
| Operating Income | $150M | -$528M |
| Net Income | $108M | -$586M |
| R&D Expense | $50M | $773M |
| SG&A Expense | $325M | $351M |
| Cost of Goods Sold | $387M | – |
Dividend & Shareholder Information
| Metric | ANIP | RARE |
|---|---|---|
| Dividends Per Share | $0.01 | – |
| Payout Ratio | 0.2% | – |
| Shares Outstanding | 23M | 99M |
| Net Income Growth | 6358.4% | – |
ANIP vs RARE: stock comparison and AI forecast
Which is bigger, ANIP or RARE?
ANIP and RARE have similar market capitalizations ($1.62B and $1.61B).
Which one does Intratio's AI model rank higher, ANIP or RARE?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.